Vimta Labs DuPont analysis

Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.74×0.75×0.76×0.75×0.74×
1.09×1.06×1.03×1.04×1.01×
23.2%24.0%25.2%15.9%20.0%
0.79×0.79×0.80×0.83×0.95×
1.21×1.23×1.23×1.25×1.28×
17.9%18.5%19.3%12.9%18.3%
18.6%18.6%19.4%13.0%18.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

VIMTALABS₹519.80

Vimta Labs Limited

· Pharma & Health
₹ CrorePeersSUVENTAKEMcap ₹2,322 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.740.750.760.750.74
Interest Burden (Pretax/EBIT) ×1.011.041.031.061.09
EBIT Margin %19.9915.8625.1924.0023.24
Asset Turnover ×0.950.830.800.790.79
Financial Leverage (Assets/Equity) ×1.281.251.231.231.21
ROE (5-step product, year-end total equity) %18.3212.8919.2918.5017.87
ROE (owners' profit / average owners' equity) %18.4013.0019.3818.5518.55
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.